Shanghai Jiaoda Withub Information Industrial Company Limited
8205.HK News Today: Stay Updated with the Latest Shanghai Jiaoda Withub Information Industrial Company Limited News in Real Time
Find 8205.HK news now at Meyka AI. Stay informed with the latest Shanghai Jiaoda Withub Information Industrial Company Limited stocks updates, including price news, market analysis, and expert insights.
鈴木福 May 01: Actor Gets MT License on Good Luck Day
Suzuki Fuku obtains MT driver’s license on April 29, trending 75% in Japan. Actor celebrates milestone on “Good Luck Day” amid fan reactions.
NWI.CN Stock Plunges 50% on April 30, 2026 – Nuinsco Resources Hits New Low
NWI.CN stock crashes 50% to C$0.005 on April 30, 2026. Nuinsco Resources Limited faces severe headwinds in Basic Materials sector.
0YU.DE: Yum China Beats Earnings Estimates
Yum China (0YU.DE) beat Q1 2026 earnings with $0.753 EPS and $2.83B revenue, exceeding estimates by 1.89% and 1.82%.
IDP.DE Biogen Inc. Earnings Beat: EPS Surges 20.7%
Biogen Inc. (IDP.DE) beats Q1 2026 earnings with $3.09 EPS vs $2.56 estimate and $2.14B revenue. Strong performance in neurological therapies.
IDP.DE Biogen Inc. Earnings Beat: Q1 2026 Results
Biogen Inc. (IDP.DE) beats earnings expectations with $3.09 EPS and $2.14B revenue on April 29, 2026.
CVVIF Stock Crashes 98.79% on April 30, 2026 – Sociedad Comercial del Plata
CVVIF stock plummets 98.79% to $0.0017 on April 30, 2026. Sociedad Comercial del Plata faces severe losses amid operational challenges.
JPY/HKD May 1: Yen Breaks 160 Barrier as Currency Crisis Deepens
Japanese yen weakens to 160 against HKD on May 1. JPY/HKD exchange rate reaches 4.875, reflecting forex volatility and carry trade pressures.
HCC.NS Stock Drops 1.6% on Apr 30, 2026 with 46.7M Shares Traded
HCC.NS stock fell 1.6% to INR 22.04 on NSE with 46.7M shares traded. Engineering & Construction firm shows mixed technical signals.
ALBPS.PA stock plunges 19.9% in after-hours trading on EURONEXT
Biophytis S.A. (ALBPS.PA) drops 19.9% in after-hours session on EURONEXT. Clinical-stage biotech faces steep decline amid market pressure.